Belimumab in adult renal transplant recipients for prevention of allograft rejection

Phase 2, randomised, double-blind trial in kidney allograft rejection comparing Benlysta plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Change from baseline in naive B cells from baseline to Week 24. Started Apr 2012; status: completed.